Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.
|Keywords||Acromegaly/drug therapy/*etiology, Adenoma/complications/*drug therapy/surgery, Adult, Antineoplastic Agents, Hormonal/*therapeutic use, Drug Therapy, Combination, Human Growth Hormone/*analogs & derivatives/blood/*therapeutic use, Humans, Insulin-Like Growth Factor I/metabolism, Male, Neoplasm Recurrence, Local/*drug therapy, Octreotide/*therapeutic use, Pituitary Neoplasms/complications/*drug therapy/surgery, Receptors, Somatotropin/antagonists & inhibitors|
Muller, A.F., Davis, R.J., Zib, K.A., Scarlett, J.A., Lamberts, S.W.J., Janssen, J.A.M.J.L., & van der Lely, A.J.. (2001). Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism. Retrieved from http://hdl.handle.net/1765/9570